Abstract
No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8-21.2%). Shorter remission after transplantation (P<0.001), advanced disease (P=0.001), older age (P=0.007), unrelated donor (P=0.008) and acute graft-versus-host disease before relapse (P<0.001) adversely influenced survival. At 6 months from relapse, patients had received no cellular treatment, (i.e. palliative chemotherapy or best supportive care, n=375), donor lymphocyte infusion (n=213), or a second transplant (n=110). Treatment groups were analyzed separately because of imbalanced characteristics and difficulties in retrospectively evaluating the reason for individual treatments. Of the patients who did not receive any cellular therapy, 109 were alive at 6 months after relapse, achieving a median overall survival from this landmark of 8.9 months (95% confidence interval: 5.1-12.6). Their 2-year survival rate was 29.7%. Rec...Continue Reading
Citations
Mar 17, 2018·Expert Review of Hematology·Guido KobbeUlrich Germing
Aug 21, 2018·Current Opinion in Oncology·Juan MontoroManuel Guerreiro
Mar 30, 2019·Annals of Hematology·Esther SchulerGuido Kobbe
Jul 20, 2019·Expert Review of Hematology·Guido KobbeUlrich Germing
Jul 30, 2019·Expert Review of Hematology·Ulrich GermingNorbert Gattermann
Sep 20, 2019·Immunological Investigations·M MerleH M Schmetzer
Jul 12, 2020·Leukemia & Lymphoma·Naveed AliShahram Mori
Jan 11, 2019·International Journal of Molecular Sciences·Christina RautenbergThomas Schroeder
Apr 9, 2020·Frontiers in Immunology·Giuseppe LiaBenedetto Bruno
Apr 4, 2019·British Journal of Haematology·Yoshimitsu ShimomuraKen Ishiyama
May 16, 2019·Journal of Immunotherapy·Annika Hirn LopezHelga Schmetzer
Sep 3, 2020·Bone Marrow Transplantation·Christina RautenbergThomas Schroeder
Aug 19, 2020·Cancers·Christina RautenbergThomas Schroeder
Nov 17, 2020·Annals of Hematology·Esther SchulerUNKNOWN German Cooperative Transplant Study Group
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph SchmidGesine Bug
Nov 5, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Guang-Shing ChengAnne Bergeron
Feb 25, 2020·Hematology/oncology Clinics of North America·Eric S Winer
Nov 30, 2020·European Journal of Haematology·Evgeny KlyuchnikovNicolaus Kröger
Nov 24, 2020·Frontiers in Oncology·Ahmad I AntarAli Bazarbachi
Apr 11, 2021·Immunobiology·M MerleH M Schmetzer
May 15, 2021·European Journal of Haematology·Christina RautenbergThomas Schroeder
Jun 30, 2021·The Journal of Molecular Diagnostics : JMD·Matthijs VynckHelena Devos
Jul 19, 2021·Bone Marrow Transplantation·Andrius ZucenkaLaimonas Griskevicius
Oct 30, 2021·Leukemia & Lymphoma·Ibrahim AldossStephen J Forman
Aug 25, 2020·Acta Pharmaceutica Sinica. B·Wei ShiHu Yu
Jan 14, 2022·JAMA Oncology·Guru Subramanian Guru MurthyWael Saber
Feb 1, 2022·Journal of Cancer Research and Clinical Oncology·Maximilian FleischmannUlf Schnetzke